FIGURE 5.
BSO does not activate CD36 transcription. RAW264.7 cells received the following treatment. A, BSO at the indicated concentrations for 16 h or with 5 μm BSO for the indicated times. B, CAT (10 units/ml), SOD (500 units/ml), NAC (10 mm), and NMMA (0.1 mm) or each plus BSO (5 μm) overnight. C, LDL or LDL plus BSO overnight. Expression of CD36 mRNA was determined by real time RT-PCR. *, p < 0.05 versus control (n = 3). D, RAW264.7 cells were treated with actinomycin D (ActD, 5 μg/ml) or actinomycin D plus BSO (5 μm) for the indicated times. Expression of CD36 and GAPDH mRNA was determined by RT-PCR. E, ∼90% confluent 293T cells were transfected with DNA for the CD36 promoter, PPARγ and RXRα expression vectors, and Renilla luciferase for 4 h followed by treatment with BSO or BSO plus pioglitazone overnight. After transfection and treatment, the cellular lysate was extracted for determination of the activity of firefly and Renilla luciferases. F, peritoneal macrophages isolated from the PPARγfl/fl and the conditional macrophage PPARγ knock-out (MacPPARγ KO) mice were treated with BSO at the indicated concentrations overnight followed by determination of PPARγ and CD36 protein expression. G, RAW264.7 cells were treated with BSO at the indicated concentrations (left panel) or BSO plus CAT as indicated (right panel) overnight. Expression of total STAT1 and pSTAT1 was determined by Western blot.